Neuren Pharmaceuticals Cash Flow Statement

Financials in millions AUD. Fiscal year is January - December.

Millions AUD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	142.04	157.08	0.18	-7.79	-9.19	Upgrade
Depreciation & Amortization	0.02	0.02	0.01	0.01	0.01	Upgrade
Loss (Gain) From Sale of Investments	-3.59	1.53	0.7	-	-	Upgrade
Stock-Based Compensation	1.23	2.93	1.99	0.84	0.39	Upgrade
Other Operating Activities	10.44	0.14	0.18	-0.4	0.72	Upgrade
Change in Accounts Receivable	-157.59	-13.11	0.19	-2.51	-0.2	Upgrade
Change in Accounts Payable	-	-	0.34	-0.11	0.19	Upgrade
Change in Income Taxes	-3.83	36.35	-	-	-	Upgrade
Operating Cash Flow	-11.27	184.93	3.6	-9.97	-8.08	Upgrade
Operating Cash Flow Growth	-	5038.23%	-	-	-	Upgrade
Capital Expenditures	-0.01	-0.04	-0.02	-0.01	-0.01	Upgrade
Investment in Securities	4.14	-211.45	-	-	-	Upgrade
Investing Cash Flow	4.13	-211.49	-0.02	-0.01	-0.01	Upgrade
Issuance of Common Stock	1.66	3.64	-	23.28	20.22	Upgrade
Repurchase of Common Stock	-10.43	-	-	-	-	Upgrade
Other Financing Activities	-0.01	-0.02	-0	-1.11	-1.08	Upgrade
Financing Cash Flow	-8.78	3.62	-0	22.18	19.14	Upgrade
Foreign Exchange Rate Adjustments	1.97	-0.15	-0.18	0.4	-0.71	Upgrade
Net Cash Flow	-13.94	-23.09	3.4	12.6	10.34	Upgrade
Free Cash Flow	-11.28	184.89	3.58	-9.98	-8.08	Upgrade
Free Cash Flow Growth	-	5064.39%	-	-	-	Upgrade
Free Cash Flow Margin	-5.20%	79.71%	23.22%	-312.17%	-1127.48%	Upgrade
Free Cash Flow Per Share	-0.09	1.41	0.03	-0.08	-0.08	Upgrade
Cash Income Tax Paid	37.22	-0.88	-1.39	-2.52	-0.49	Upgrade
Levered Free Cash Flow	-42.25	152.97	2.59	-6.76	-5.12	Upgrade
Unlevered Free Cash Flow	-42.25	152.97	2.59	-6.76	-5.12	Upgrade
Change in Net Working Capital	155.47	-25.53	-1.07	2.46	0.01	Upgrade

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.